Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic

Chemical Compounds

• Angiogenic 100%
• Small Interfering RNA 94%
• Silencing RNA 88%
• Antitumor 62%
• Nucleic Acid 57%
• Drug 35%

Medicine & Life Sciences

• Urokinase Plasminogen Activator Receptors 95%
• Plasminogen Activators 17%
• Urokinase-Type Plasminogen Activator 16%
• Therapeutics 11%
• Neoplasms 9%
• Small Interfering RNA 8%
• Drug Stability 6%
• Neoplasm Antigens 5%
• Hematologic Neoplasms 4%
• Multiple Myeloma 4%
• Nucleic Acids 4%
• Integrins 4%
• Wound Healing 4%
• Cell Movement 3%
• Leukemia 3%
• Endothelial Cells 3%
• Macrophages 3%
• RNA 3%
• Clinical Studies 3%